Monte Rosa Therapeutics is a biotechnology company developing small molecules to degrade disease-related proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. Monte Rosa was launched from founding investor Versant Ventures' Ridgeline Discovery Engine based in the Basel Technology Park.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/26/20 | $32,500,000 | Series A |
New Enterprise Associates Versant Ventures | undisclosed |
| 03/12/21 | $95,000,000 | Series C |
Aisling Capital Amzak Capital Management Avoro Capital Advisors  BlackRock Fidelity Management & Research Company GV HBM Healthcare Investments New Enterprise Associates RTW Investments T. Rowe Price Associates Versant Ventures | undisclosed |
